Research programme: obesity therapy - AdipoGenix/Johnson And Johnson

Drug Profile

Research programme: obesity therapy - AdipoGenix/Johnson And Johnson

Latest Information Update: 13 Apr 2012

Price : $50

At a glance

  • Originator AdipoGenix; Johnson & Johnson
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Obesity

Most Recent Events

  • 16 Mar 2006 AdipoGenix achieved its third milestone in the collaboration with Johson And Johnson
  • 20 Nov 2003 AdipoGenix has completed the initial screening of compounds selected by Johnson & Johnson
  • 19 Dec 2002 Preclinical trials in Obesity in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top